Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
Open accessAbstract
This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66 ± 1.47 vs -0.71 ± 1.09, P = 0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verbal fluency test (P < 0.05). Similar to MCI subjects, Aβ+ CN subjects showed greater decline on the ADAS-Cog, digit-symbol-substitution test and verbal fluency (P<0.05), whereas Aβ+ AD patients showed greater declines in verbal fluency and the MMSE (P < 0.05). Aβ+ subjects in all diagnostic groups also showed greater decline on the CDR-SB (P<0.04), a global clinical assessment. Aβ+ subjects did not show significantly greater declines on the ADCS-ADL or Wechsler Memory Scale. Overall, these findings suggest that in CN, MCI and AD subjects, florbetapir PET Aβ+ subjects show greater cognitive and global deterioration over a 3-year follow-up than Aβ- subjects do.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Amyloid PET positive status in 69 cognitively normal, 52 MCI, and 31 AD was associated with greater cognitive and global deterioration over a 3-year follow-up compared to amyloid PET negative subjects.
“Amyloid PET positive status in 69 cognitively normal, 52 MCI and 31 AD was shown to be associated with greater cognitive and global deterioration over a 3 year follow up compared to amyloid PET negative subjects showing prognostic potential [170].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · see citing works
Self-citationMorris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works
Self-citationAmyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study
Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · see citing works
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186 · see citing works
Flagged first, then by citations
Research works printed but not linked: 35
- Aisen PS Andrieu S Sampaio C Carrillo M Khachaturian ZS Dubois B Report of the task force on designing clinical trials in early (predementia) AD Neurology. Jan 2011 76 280 286 PMC3034393 21178097
- Weiner MW Aisen PS Jack CR Jr. Jagust WJ Trojanowski JQ Shaw L The Alzheimer's disease neuroimaging initiative: progress report and future plans Alzheimers Dement 2010 6 202 211 e207 20451868 PMC2927112
- Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease Neurobiol Aging 1997 18 ((4 Suppl S1 S2 9330978
- Fleisher AS Chen K Quiroz YT Jakimovich LJ Gomez MG Langois CM Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study Lancet Neurol 2012 11 1057 1065 23137949 PMC3515078
- Bateman RJ Xiong C Benzinger TL Fagan AM Goate A Fox NC Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 2012 367 795 804 22784036 PMC3474597
- Sperling RA Aisen PS Beckett LA Bennett DA Craft S Fagan AM Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 2011 7 280 292 21514248 PMC3220946
- Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 2004 55 306 319 14991808
- Nordberg A Rinne JO Kadir A Langstrom B The use of PET in Alzheimer disease Nat Rev Neurol 2010 6 78 87 20139997
- Okello A Koivunen J Edison P Archer HA Turkheimer FE Någren K Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 2009 73 754 760 19587325 PMC2830881
- Jack CR Jr. Wiste HJ Vemuri P Weigand SD Senjem ML Zeng G Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 2010 133 3336 3348 20935035 PMC2965425
- Villemagne VL Pike KE Darby D Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease Neuropsychologia 2008 46 1688 1697 18343463
- Wolk DA Price JC Saxton JA Snitz BE James JA Lopez OL Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 2009 65 557 568 19475670 PMC2828870
- Storandt M Mintun MA Head D Morris JC Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition Arch Neurol 2009 66 1476 1481 20008651 PMC2796577
- Resnick SM Sojkova J Zhou Y Zhou Y An Y Ye W Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB Neurology 2010 74 807 815 20147655 PMC2839197
- Lim YY Ellis KA Pietrzak RH Ames D Darby D Harrington K Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults Neurology 2012 79 1645 1652 23071163
- Pontecorvo MJ Mintun MA PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease Alzheimers Res Ther 2011 3 11 21457498 PMC3226273
- Choi SR Golding G Zhuang Z Zhang W Lim N Hefti F Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain J Nucl Med 2009 50 1887 1894 19837759 PMC3065020
- Clark CM Schneider JA Bedell BJ Beach TG Bilker WB Mintun MA Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 2011 305 275 283 21245183 PMC7041965
- Barthel H Gertz HJ Dresel S Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study Lancet Neurol 2011 10 424 435 21481640
- Rowe CC Ackerman U Browne W Mulligan R Pike KL O'Keefe G Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 2008 7 129 135 18191617
- Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging Alzheimers Dement 2013 9 ((5 Suppl S72 S83 23375563 PMC3800236
- Sperling RA Johnson KA Doraiswamy PM Reiman EM Fleisher AS Sabbagh MN Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiol Aging 2013 34 822 831 22878163 PMC3518678
- Doraiswamy PM Sperling RA Coleman RE Johnson KA Reiman EM Davis MD Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study Neurology 2012 79 1636 1644 22786606 PMC3468774
- McKhann G Drachman D Folstein M Katzman R Price D Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 1984 34 939 944 6610841
- Fleisher AS Chen K Liu X Roontiva A Thiyyagura P Ayutyanont N Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease Arch Neurol 2011 68 1404 1411 21747008
- Rowe CC Ellis KA Rimajova M Bourgeat P Pike KE Jones G Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 2010 31 1275 1283 20472326
- Rogers SL Farlow MR Doody RS Mohs R Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurology 1998 50 136 145 9443470
- Tariot PN Solomon PR Morris JC Kershaw P Lilienfeld S Ding C A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group Neurology 2000 54 2269 2276 10881251
- Rosler M Anand R Cicin-Sain A Gauthier S Agid Y Dal-Bianco P Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial BMJ 1999 318 633 638 10066203 PMC27767
- Aisen PS Petersen RC Donohue MC Gamst A Raman R Thomas RG Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans Alzheimers Dement 2010 6 239 246 20451872 PMC2867843
- Ramanan VK Risacher SL Nho K Kim S Swaminathan S Shen L APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatryadvance online publication, 19 February 2013; doi: 10.1038/mp.2013.19 PMC3661739 23419831 · DOI
- Weiner MW Veitch DP Aisen PS Beckett LA Cairns NJ Green RC The Alzheimer's disease neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 2012 8 ((1 Suppl S1 68 22047634 PMC3329969
- Wu L Rowley J Mohades S Leuzy A Dauar MT Shin M Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment PLoS ONE 2012 7 e47905 23112868 PMC3480449
- Landau SM Mintun MA Joshi AD Koeppe RA Petersen RC Aisen PS Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol 2012 72 578 586 23109153 PMC3786871
- Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doraiswamy PM Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study Lancet Neurol 2012 11 669 678 22749065
Cited by
Sorted by citations
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761 · see citing works
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · see citing works
Self-citationImaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 440 · see citing works
Kueper, J. K., Speechley, M. R., & Montero‐Odasso, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170991 · Cited by 434 · see citing works
Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease
de Florès, R., Joie, R. L., & Chételat, G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.033 · Cited by 363 · see citing works
Hsu, J., Wei, Y., Toh, C., Hsiao, I., Lin, K., Yen, T., Liao, M., & Ro, L. (2022) · Annals of Neurology · doi:10.1002/ana.26516 · Cited by 261 · see citing works
Ocular indicators of Alzheimer’s: exploring disease in the retina
Hart, N. J., Koronyo, Y., Black, K. L., & Koronyo‐Hamaoui, M. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1613-6 · Cited by 260 · see citing works
“, (11)C-Pittsburgh compound B, PiB [125], (18)F-florbetapir [45], (18)F-flutemetamol [80], (18)F-florbetaben [173], (18)F-TKH5105, and (18)F-T807 [89]) provides disease specificity and facilitates ongoing research.”
Pontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249 · see citing works
“…to Alzheimer’s disease have been shown to have worse cognitive performance (Pike et al., 2007; Johnson et al., 2013), and to deteriorate more rapidly (Doraiswamy et al., 2014; Ma et al., 2014; Baker et al., 2017), if amyloid-positive (amyloid-b + ) than if amyloidnegative (amyloid-b ) by PET scan.”
BackgroundSelf-citationPietrzak, R. H., Lim, Y. Y., Neumeister, A., Ames, D., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Restrepo, C., Martins, R. N., Masters, C. L., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2476 · Cited by 214 · see citing works
Blennow, K., Shaw, L. M. J., Stomrud, E., Mattsson, N., Toledo, J. B., Buck, K., Wahl, S., Eichenlaub, U., Lifke, V., Simon, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54204-z · Cited by 193 · see citing works
Petersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196 · see citing works
Baker, J. E., Lim, Y. Y., Pietrzak, R. H., Hassenstab, J. J., Snyder, P. J., Masters, C. L., & Maruff, P. T. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.09.002 · Cited by 203 · see citing works
“Reference lists of articles were also screened for key citations, and newly published articles were screened for relevance.”
BackgroundThe use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 186 · see citing works
“Amyloid PET positive status in 69 cognitively normal, 52 MCI and 31 AD was shown to be associated with greater cognitive and global deterioration over a 3 year follow up compared to amyloid PET negative subjects showing prognostic potential [170].”
ResultAmadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00587-5 · Cited by 181 · see citing works
SPECT and PET imaging in Alzheimer’s disease
Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., Alexiou, S., Hadjigeorgiou, G., & Georgoulias, P. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1292-6 · Cited by 169 · see citing works
Chandra, A., Valkimadi, P., Pagano, G., Cousins, O., Dervenoulas, G., Politis, M., & Initiative, A. D. N. (2019) · Human Brain Mapping · doi:10.1002/hbm.24782 · Cited by 185 · see citing works
“AD patients rated as Aβ positive showed a similar pattern on measures of global cognition and verbal fluency (Doraiswamy et al., 2014).”
BackgroundBeta-amyloid imaging with florbetaben
Sabri, O., Seibyl, J., Rowe, C., & Barthel, H. (2015) · Clinical and translational imaging · doi:10.1007/s40336-015-0102-6 · Cited by 167 · see citing works
“However, especially at the prodromal AD stage of mild cognitive impairment (MCI) and even at the dementia stage of this disease, clinical testing lacks accuracy to establish a reliable AD diagnosis [3, 4].”
BackgroundOttoy, J., Niemantsverdriet, E., Verhaeghe, J., De Roeck, E., Struyfs, H., Somers, C., wyffels, L., Ceyssens, S., Van Mossevelde, S., Van den Bossche, T., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101771 · Cited by 151 · see citing works
“Indeed, whereas amyloid-PET was found to be a predictor of future cognitive decline (Ben Bouallègue et al., 2017; Doraiswamy et al., 2014; Farrell et al., 2017; Landau et al., 2012), CSF Aβ had a rather limited prognostic value (Ben Bouallègue et al.”
Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 201 · see citing works
The Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133 · see citing works
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133 · see citing works
“Existing prospective studies sug- gest that brain amyloid accumulation occurs over decades, preceding the onset of clinical symptoms and subsequently contributing to clinical progression (Villemagne et al., 2013; Doraiswamy et al., 2014; Huijbers et al., 2015).”
BackgroundRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 82 · see citing works
“…studies, numerous reports have found that, allowing for adequate follow-up duration, a majority of MCI patients with a positive amyloid PET scan will progress to AD dementia, whereas the risk of progression to AD dementia is signi fi cantly lower in those who are amyloid negative ( 213 – 219 ).”
Self-citationHypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Soldan, A., Pettigrew, C. A., Cai, Q., Wang, M., Moghekar, A., O’Brien, R., Selnes, O. A., & Albert, M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 117 · see citing works
Alzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 130 · see citing works
Measuring cognition and function in the preclinical stage of Alzheimer's disease
Weintraub, S., Carrillo, M., Farias, S., Goldberg, T., Hendrix, J. A., Jaeger, J., Knopman, D., Langbaum, J., Park, D. C., Ropacki, M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.trci.2018.01.003 · Cited by 120 · see citing works
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 151 · see citing works
Self-citationPRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE
Hampel, H. J., O’Bryant, S. E., Castrillo, J. I., Ritchie, C. W., Rojkova, K., Broich, K., Benda, N., Nisticò, R., Frank, R., Dubois, B., et al. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.112 · Cited by 116 · see citing works
“Subsequent work has provided confirmatory evidence in support of this conclusion (134,135) and similar results are being obtained with PET agents imaging tau (136,137), relevant to the precision administration of therapeutic interventions targeting tau.”
Nonvascular retinal imaging markers of preclinical Alzheimer's disease
Snyder, P. J., Johnson, L. N., Lim, Y. Y., Santos, C. Y., Alber, J., Maruff, P. T., & Fernandez, B. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.09.001 · Cited by 115 · see citing works
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110 · see citing works
Lim, Y., Snyder, P., Pietrzak, R., Ukiqi, A., Villemagne, V., Ames, D., Salvado, O., Bourgeat, P., Martins, R., Masters, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.dadm.2015.11.003 · Cited by 107 · see citing works
PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
James, O. G., Doraiswamy, P. M., & Borges-Neto, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00038 · Cited by 104 · see citing works
Self-citationDetectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
Han, S. D., Nguyen, C. P., Stricker, N. H., & Nation, D. A. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9345-5 · Cited by 108 · see citing works
“…et al. (2014) PET 60 37 74.8 5.4 77.5 4.7 15.2 2.9 15.5 3.2 50 32 Doraiswamy et al. (2012) PET 59 10 68.5 11.3 77.3 8 15.2 2.4 15.9 0.7 62.7 40 Doraiswamy et al. (2014) PET 57 10 68.7 11.3 77.3 8 15.2 2.4 15.9 0.7 63.2 40 Edmonds et al. (2015) CSF 142 48 72.3 6.8 71.8 6.7 16.2 2.6 16.1 3 48.6…”
InfluentialGamberger, D., Lavrač, N., Srivatsa, S., Tanzi, R., & Doraiswamy, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-06624-y · Cited by 92 · see citing works
Self-citationAccelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M. S., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 97 · see citing works
Self-citationPietrzak, R. H., Lim, Y. Y., Ames, D. J., Harrington, K., Restrepo, C., Martins, R. N., Rembach, A., Laws, S. M., Masters, C. L., Villemagne, V. L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.015 · Cited by 84 · see citing works
Pietrzak, R. H., Laws, S. M., Lim, Y. Y., Bender, S. J., Porter, T., Doecke, J. D., Ames, D. J., Fowler, C. J., Masters, C. L., Milicic, L., et al. (2016) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2016.08.006 · Cited by 63 · see citing works
Wolk, D., Sadowsky, C., Safirstein, B., Rinne, J., Duara, R., Perry, R., Agronin, M., Gámez, J. E., Shi, J., Ivanoiu, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0894 · Cited by 83 · see citing works
Self-citationSchreiber, S., Landau, S., Fero, A., Schreiber, F., & Jagust, W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1633 · Cited by 83 · see citing works
Lim, Y., Maruff, P., Getter, C., & Snyder, P. J. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.005 · Cited by 81 · see citing works
Lim, Y., Kalinowski, P., Pietrzak, R., Laws, S., Burnham, S., Ames, D., Villemagne, V., Fowler, C., Rainey-Smith, S., Martins, R., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4325 · Cited by 80 · see citing works
Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later
Joutsa, J., Rinne, J. O., Hermann, B. P., Karrasch, M., Anttinen, A., Shinnar, S., & Sillanpää, M. L. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6091 · Cited by 75 · see citing works
Clark, L. R., Racine, A. M., Koscik, R. L., Okonkwo, O. C., Engelman, C. D., Carlsson, C. M., Asthana, S., Bendlin, B. B., Chappell, R. J., Nicholas, C. R. N., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.12.009 · Cited by 75 · see citing works
Ruan, Q., D’Onofrio, G., Sancarlo, D., Bao, Z., Greco, A., & Yu, Z. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0281-7 · Cited by 79 · see citing works
“tive subjects [70, 71] and Aβpositive subjects of MCI had higher risk for conversion to AD than Aβnegative”
BackgroundSubjective cognitive decline and β-amyloid burden predict cognitive change in healthy elderly
Vogel, J. W., Doležalová, M. V., Joie, R. L., Marks, S. M., Schwimmer, H., Landau, S. M., & Jagust, W. J. (2017) · Neurology · doi:10.1212/wnl.0000000000004627 · Cited by 71 · see citing works
(ADNI), T. A. D. N. I., Bouallègue, F. B., Mariano‐Goulart, D., & Payoux, P. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0260-z · Cited by 71 · see citing works
“Researchers in several studies have reported the capacity of amyloid PET using fluorinated tracers (either visual [21], semi-quantitative [22, 23] or both [24]) to provide prognostic insight regarding cognitive decline and conversion to AD in patients with MCI, in line with previous evidence of the prognostic value of…”
ResultHarrison, T. M., Mahmood, Z., Lau, E., Karacozoff, A. M., Burggren, A., Small, G., & Bookheimer, S. (2016) · eNeuro · doi:10.1523/eneuro.0098-16.2016 · Cited by 67 · see citing works
“According to Doraiswamy et al. (2014), 14% of cognitively healthy older subjects are amyloid positive.”
BackgroundAlzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 66 · see citing works
“These tracers correlate with brain amyloid burden and successfully predict AD progression in patients with MCI [25 – 29].”
Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project
Timmers, T., Ossenkoppele, R., Verfaillie, S. C. J., van der Weijden, C. W. J., Slot, R. E. R., Wesselman, L. M. P., Windhorst, A. D., Wolters, E. E., Yaqub, M., Prins, N. D., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.020 · Cited by 63 · see citing works
Multicenter stability of resting state fMRI in the detection of Alzheimer’s disease and amnestic MCI
Teipel, S. J., Wohlert, A., Metzger, C., Grimmer, T., Sorg, C., Ewers, M., Meisenzahl, E., Klöppel, S., Borchardt, V., Grothe, M. J., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.01.018 · Cited by 62 · see citing works
“All these imaging markers have already been evaluated in large multicenter cohorts, such as ADNI, EDSD, NEST-DD and others (Doraiswamy et al., 2014; Herholz, 2010; Kilimann et al., 2014; Risacher et al., 2009).”
MethodMartínez, G., Vernooij, R. W. M., Padilla, P. F., Zamora, J., Bonfill, X., & Flicker, L. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012216.pub2 · Cited by 59 · see citing works
Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers
Dang, C., Wang, Y., Li, Q., & Lu, Y. (2023) · Psychoradiology · doi:10.1093/psyrad/kkad009 · Cited by 53 · see citing works
“It has been reported that [ 18 F]florbetapir-positive scans wer e pr edictiv e for pr ogr essiv e deterior ation of cognitiv e states in MCI and AD patients, compared with those with a negative scan (Doraiswamy et al. , 2014 ).”
ResultSecondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 60 · see citing works
Verberk, I. M. W., Hendriksen, H. M. A., van Harten, A. C., Wesselman, L. M. P., Verfaillie, S. C. J., van den Bosch, K. A., Slot, R. E. R., Prins, N. D., Scheltens, P., Teunissen, C. E., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.007 · Cited by 57 · see citing works
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 64 · see citing works
Lim, Y., Pietrzak, R., Bourgeat, P., Ames, D., Ellis, K., Rembach, A., Harrington, K., Salvado, O., Martins, R., Snyder, P., et al. (2015) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acu068 · Cited by 53 · see citing works
“When considered together, the results of the current study are consistent with those of previous studies, which have suggested that, in non-demented older individuals, Ab+ is not a benign process and is associated with increased decline in episodic and working memory and HV (Chételat et al., 2012; Doraiswamy et al., 2…”
BackgroundResultInfluence of amyloid and APOE on cognitive performance in a late middle-aged cohort
Mielke, M., Machulda, M., Hagen, C. E., Christianson, T., Roberts, R., Knopman, D., Vemuri, P., Lowe, V., Kremers, W. K., Jack, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.010 · Cited by 51 · see citing works
Initiative, A. D. N., Zhu, X., Wang, H.-F., Jiang, T., Lu, H., Tan, M., Tan, C., Tan, L., Tan, L., & Yu, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9638-8 · Cited by 26 · see citing works
Witte, M. M., Foster, N. L., Fleisher, A., Williams, M., Quaid, K. A., Wasserman, M. R., Hunt, G., Roberts, J. S., Rabinovici, G. D., Levenson, J. L., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.06.006 · Cited by 44 · see citing works
Self-citationNayate, A. P., Dubroff, J. G., Schmitt, J. E., Nasrallah, I. M., Kishore, R., Mankoff, D. A., Pryma, D. A., & Initiative, A. D. N. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4281 · Cited by 52 · see citing works
Jang, H., Park, J., Woo, S., Kim, S., Kim, H. J., Na, D. L., Lockhart, S. N., Kim, Y., Kim, K. W., Cho, S. H., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101941 · Cited by 46 · see citing works
“Previous studies have shown that 40–60% of MCI patients are Aβ positive (Aβ +) on PET; these patients are classified as MCI due to AD, with evidence of 40% to 80% risk of conversion to AD dementia within 3 years, a level that is 4 to 9 fold higher than their Aβ negative counterparts (Doraiswamy et al., 2014; Okello et…”
Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies
Gomperts, S. N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0472-6 · Cited by 46 · see citing works
Koychev, I., Hofer, M., & Friedman, N. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230458 · Cited by 44 · see citing works
“More broadly, long-term follow-up data of amyloid-positive individuals have shown a tendency for greater cognitive decline relative to those with no significant Ab burden (32,33).”
BackgroundCurrent Perspectives regarding Stem Cell-Based Therapy for Alzheimer’s Disease
Kwak, K.-A., Lee, S., Yang, J.-Y., & Park, Y. (2018) · Stem Cells International · doi:10.1155/2018/6392986 · Cited by 50 · see citing works
“However, approximately onethird of patients with a documented diagnosis of AD have no radiographic signs of amyloid on PET scans [9].”
BackgroundEffectiveness of Florbetapir PET Imaging in Changing Patient Management
Pontecorvo, M., Siderowf, A., Dubois, B., Doraiswamy, P., Frisoni, G., Grundman, M., Nobili, F., Sadowsky, C., Salloway, S., Arora, A. K., et al. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000478007 · Cited by 44 · see citing works
Self-citationNeuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 48 · see citing works
Dementia spectrum disorders: lessons learnt from decades with PET research
Wilson, H., Pagano, G., & Politis, M. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01975-4 · Cited by 48 · see citing works
Gamberger, D., Ženko, B., Mitelpunkt, A., Shachar, N., & Lavrač, N. (2016) · Brain Informatics · doi:10.1007/s40708-016-0035-5 · Cited by 42 · see citing works
“Published results obtained with these methods [7, 8] clearly demonstrate the existence of”
ResultAmyloid involvement in subcortical regions predicts cognitive decline
Cho, S., Shin, J.-H., Jang, H., Park, S., Kim, H., Kim, S. E., Kim, S., Kim, Y., Lee, J.-S., Na, D., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4081-5 · Cited by 40 · see citing works
“There have been recent reports that amyloid-positive people show more rapid cognitive decline [27, 28].”
Fleisher, A., Joshi, A. D., Sundell, K. L., Chen, Y., Kollack‐Walker, S., Lu, M., Chen, S., Devous, M. D., Seibyl, J. P., MAREK, K. L., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.009 · Cited by 39 · see citing works
Self-citationAmyloid Imaging: Poised for Integration into Medical Practice
Anand, K., & Sabbagh, M. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0474-y · Cited by 39 · see citing works
“demonstrated no significant decline on the ADL or the Wechsler logical memory scale [27].”
BackgroundSelf-citationEstimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program.
Arbanas, J., Damberg, C., Leng, M., Harawa, N. T., Sarkisian, C., Landon, B., & Mafi, J. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1749 · Cited by 38 · see citing works
Recent imaging advances in neurology
Rocchi, L., Niccolini, F., & Politis, M. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7711-x · Cited by 39 · see citing works
“Ab-amyloid PET imaging such as with [(18)F]Florbetapir has been shown to be predictive of cognitive and global deterioration over a 3-year follow-up in patients with MCI and probable AD [90].”
MethodClinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
Vāvere, A. L., & Scott, P. J. H. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.05.001 · Cited by 38 · see citing works
Neuroimaging in aging and neurologic diseases
Risacher, S. L., & Saykin, A. J. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00012-1 · Cited by 54 · see citing works
“This amyloid signal on PET is associated with cognitive performance, future decline, and the extent of amyloid plaques at autopsy (Ikonomovic et al., 2008; Doraiswamy et al., 2014).”
BackgroundCognitive composite score association with Alzheimer’s disease plaque and tangle pathology
Malek-Ahmadi, M., Chen, K.-W., Perez, S. E., He, A., & Mufson, E. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0401-z · Cited by 34 · see citing works
The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study
Biundo, R., Weis, L., Fiorenzato, E., Pistonesi, F., Cagnin, A., Bertoldo, A., Anglani, M., Cecchin, D., & Antonini, A. (2021) · Brain Communications · doi:10.1093/braincomms/fcab180 · Cited by 39 · see citing works
Geerts, H., Spiros, A., & Roberts, P. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0343-5 · Cited by 33 · see citing works
“…focus on the following clinical datasets: the absolute ADAS-Cog values for minimal cognitive impairment (MCI) subjects with and without A β load [17]; the impact of A β on cholinergic dysfunction in MCI patients [18]; and the effect of differential A β clearance associated with the APOE…”
BackgroundMethodInfluentialLee, Y.-S., Youn, H., Jeong, H., Lee, T.-J., Han, J. W., Park, J. H., & Kim, K. W. (2021) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-021-00300-9 · Cited by 33 · see citing works
Madrasi, K., Das, R., Mohmmad-Abdul, H., Lin, L., Hyman, B., Lauffenburger, D., Albers, M. W., Rissman, R., Burke, J., Apgar, J., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12312 · Cited by 32 · see citing works
Odor identification ability predicts PET amyloid status and memory decline in older adults
Kreisl, W., Jin, P., Lee, S., Dayan, E., Vallabhajosula, S., Pelton, G., Luchsinger, J., Pradhaban, G., & Devanand, D. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170960 · Cited by 32 · see citing works
Harrington, K., Lim, Y., Ames, D., Hassenstab, J. J., Laws, S., Martins, R., Rainey-Smith, S., Robertson, J., Rowe, C., Salvado, O., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.dadm.2017.05.006 · Cited by 32 · see citing works
Tosun, D., Chen, Y.-F., Yu, P., Sundell, K. L., Suhy, J., Siemers, E., Schwarz, A. J., & Weiner, M. W. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.009 · Cited by 32 · see citing works
“In contrast, people with positive Ab scans declined, with MMSE scores diverging significantly from Ab negatives at 6 months, and ADAS-Cog11 scores at 24 months [39], similar to what we observed in these global clinical trial data (Figs.”
InfluentialBangma, D. F., Tucha, O. M., Tucha, L., Deyn, P. P. D., & Koerts, J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.021 · Cited by 36 · see citing works
Fingerprints of brain disease: connectome identifiability in Alzheimer’s disease
Stampacchia, S., Asadi, S., Tomczyk, S., Ribaldi, F., Scheffler, M., Lövblad, K., Pievani, M., Fall, A. B., Preti, M. G., Unschuld, P. G., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06829-8 · Cited by 30 · see citing works
Mihelčić, M., Šimić, G., Leko, M. B. B., Lavrač, N., Džeroski, S., & Šmuc, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187364 · Cited by 28 · see citing works
“Doraiswarny et al. [33] studied PET images in the presence of cognitive decline.”
BackgroundLilamand, M., Cesari, M., Campo, N. D., Cantet, C., Soto, M., Ousset, P., Payoux, P., Andrieu, S., & Vellas, B. (2016) · The journals of gerontology. Series A, Biological sciences and medical sciences · doi:10.1093/gerona/glv155 · Cited by 28
“faster cognitive decline compared to their amyloid negative counterparts and are at higher risk of progressing to AD dementia (5,6).”
BackgroundPredicting Alzheimer’s Disease Using Combined Imaging-Whole Genome SNP Data
Kong, D., Initiative, A. F. T. A. D. N., Giovanello, K. S., Wang, Y., Lin, W., Lee, E., Fan, Y., Murali Doraiswamy, P., & Zhu, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150164 · Cited by 26 · see citing works
“The growing public threat of Alzheimer’s disease (AD) has raised the urgency to discover and validate prognostic biomarkers that may identify subjects at greatest risk for future cognitive decline and accelerate the testing of preventive strategies [1][2].”
Self-citationReduced brain amyloid burden in elderly patients with narcolepsy type 1
Gabelle, A., Jaussent, I., Bouallègue, F. B., Lehmann, S., Lopez, R., Barateau, L., Grasselli, C., Pesenti, C., de Verbizier, D., Béziat, S., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25373 · Cited by 33 · see citing works
“46 The mechanism underlying abnormal A β metabolism in NT1 remains unclear, but orexin de fi ciency, neuroin fl ammation, and abnormal sleep – wake patterns could be involved in brain amyloidosis.”
Stem cells as a promising therapeutic approach for Alzheimer’s disease: a review
Fouad, G. I. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0078-x · Cited by 34 · see citing works
Tolbert, S., Liu, Y., Hellegers, C., Petrella, J. R., Weiner, M., Wong, T., & Doraiswamy, P. M. (2019) · The journal of prevention of Alzheimer's disease · doi:10.14283/jpad.2019.26 · Cited by 24
Self-citationMachine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment
Kang, S. H., Cheon, B. K., Kim, J., Jang, H., Kim, H. J., Park, K. W., Noh, Y., Lee, J. S., Ye, B. S., Na, D. L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201092 · Cited by 26 · see citing works
Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review
Chung, J. K., Nakajima, S., Plitman, E., Iwata, Y., Uy, D., Gerretsen, P., Caravaggio, F., Chakravarty, M. M., & Graff‐Guerrero, A. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.03.013 · Cited by 24 · see citing works
Lim, Y., Villemagne, V., Laws, S., Pietrzak, R., Ames, D., Fowler, C., Rainey-Smith, S., Snyder, P., Bourgeat, P., Martins, R., et al. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0822-8 · Cited by 22 · see citing works
“…that in non-demented older adults, an elevated level of beta-amyloid (Aβ), determined from positron emission tomography (PET) or cerebral spinal fluid (CSF) sampling, is associated with cognitive decline particularly in episodic memory (Doraiswamy et al. 2014, Fagan et al. 2007, Lim et al. 2014).”
BackgroundAmyloid-β plaque deposition measured using propagation-based X-ray phase contrast CT imaging
Astolfo, A., Lathuilière, A., Laversenne, V., Schneider, B. L., & Stampanoni, M. (2016) · Journal of Synchrotron Radiation · doi:10.1107/s1600577516004045 · Cited by 22 · see citing works
“This opened also the possibility of further investigating the deposition of A p in AD patients, especially at a preclinical stage (Nordberg et al., 2010; Doraiswamy et al., 2014).”
BackgroundPredicting conversion from mild cognitive impairment to Alzheimer’s disease: a multimodal approach
Agostinho, D., Simões, M., & Castelo-Branco, M. (2024) · Brain Communications · doi:10.1093/braincomms/fcae208 · Cited by 20 · see citing works
“In Doraiswamy et al ., 26 Florbetapir PET scans were qualitatively rated as positive or negative amyloid-β (A β ), according to the tracer retention in different areas.”
BackgroundEstimated Annual Spending on Aducanumab in the US Medicare Program
Mafi, J., Leng, M., Arbanas, J., Tseng, C.-H., Damberg, C., Sarkisian, C., & Landon, B. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4495 · Cited by 20 · see citing works
The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies
Chiotis, K., Wang, Y.-B., Joie, R. L., & Rabinovici, G. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268339 · Cited by 20 · see citing works
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 19 · see citing works
“radioligand retention as the standardized uptake value ratio (SUVR) — a radioactivity ratio between the target and reference regions in a steady binding state — is employed for detecting Aβ deposition at a relatively early stage and for robust outcome measurements in clinical trials 25–27 (Fig.”
Sex Differences in in vivo Alzheimer’s Disease Neuropathology in Late Middle-Aged Hispanics
Luchsinger, J. A., Palta, P., Rippon, B., Soto, L., Ceballos, F., Pardo, M., Laing, K. K., Igwe, K. C., Johnson, A. S., Tomljanovic, Z., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191183 · Cited by 18 · see citing works
“…our study and previous studies may include that our study focused on a narrow age range in late middle age, when invivo amyloidaccumulationfirstbecomesevi-dent [33], before plateauing of amyloid accumulation occurs in older age [34], and differences in amyloid accumulation may not be apparent.”
Homogeneous clusters of Alzheimer’s disease patient population
Gamberger, D., Ženko, B., Mitelpunkt, A., & Lavrač, N. (2016) · BioMedical Engineering OnLine · doi:10.1186/s12938-016-0183-0 · Cited by 19 · see citing works
“On the other side, although relations between some biological descriptors and AD diagnosis have been undoubtedly demonstrated [3, 4], currently known biological descriptors are non-specific (e.”
Background
- Authors
- AV45-A11 Study Group, Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., Joshi, A. D., Lu, M., Grundman, M., Mintun, M. A., Skovronsky, D. M., & Pontecorvo, M. J.
- Affiliations
- Duke Medical Center (US)
- Harvard University (US)
- Nova Southeastern University (US)
- University of California San Diego (US)
- Avid Radiopharmaceuticals (United States) (US)
- Corresponding author
- Doraiswamy, P M
- Pontecorvo, M J
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2014-03-11
- Volume
- 19
- Issue
- 9
- Pages
- 1044-1051
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC4195975
- OpenAlex
- W2159123476
- Cited by
- 195
- References
- 48
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 9 · 2023: 10 · 2022: 9 · 2021: 12 · 2020: 15 · 2019: 18 · 2018: 26 · 2017: 25 · 2016: 30 · 2015: 22 · 2014: 6
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (unspecified)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Alzheimer's Association
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- Arizona Department of Health Services
- TauRx Pharmaceuticals
- National University of Singapore
- Eisai
- H. Lundbeck A/S
- Grifols
- Genentech
- National Institute on Aging
- National Heart, Lung, and Blood Institute
- National Institute of Mental Health
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- florbetapir PET, amyloid-beta pathology, cognitive decline, mild cognitive impairment, Alzheimer's dementia, amyloid PET, ADAS-Cog, functional decline, verbal fluency
- MeSH terms
- Aged, Alzheimer Disease, Aniline Compounds, Brain, Ethylene Glycols, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Prospective Studies, Amyloid beta-Peptides, Disease Progression, Nootropic Agents, Radiopharmaceuticals, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
